Core Scientific Inc's next confirmed earnings release is scheduled for March 30, 2027.
| Earnings Date | 3/30/2027 |
As of September 30, 2026, Core Scientific Inc has 321.97M shares outstanding.
| Shares Outstanding | 321.97M |
As of September 30, 2026, Core Scientific Inc maintains a current ratio of 0.67, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -393.94, indicating conservative leverage, while an interest coverage ratio of -76.23 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.67 |
| Quick Ratio | 0.52 |
| Debt / Equity | -393.94 |
| Debt / EBITDA | -11.62 |
| Interest Coverage | -76.23 |
These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -2.68, reflecting losses generated across the asset base. The company generates approximately 1.52M in revenue per employee across its workforce of 325.00, a quick read on workforce productivity versus industry peers.
| Return on Assets (ROA) | -2.68 |
| Revenue Per Employee | 1.52M |
| Employee Count | 325.00 |
Over the twelve months ended September 30, 2026, Core Scientific Inc recorded an income tax benefit of -86.69M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -178.64M and -91.95M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -86.69M |
Over the twelve months ended September 30, 2026, Core Scientific Inc generated 493.96M in revenue and converted that into -91.95M in net income, yielding earnings per share of -0.23. EBITDA reached -308.90M, while operating income came in at -60.23M.
| Revenue | 493.96M |
| Gross Profit | 203.71M |
| Operating Income | -60.23M |
| Pretax Income | -178.64M |
| Net Income | -91.95M |
| EBITDA | -308.90M |
| EBIT | -365.00M |
| Earnings Per Share (EPS) | -0.23 |
As of September 30, 2026, Core Scientific Inc holds 670.72M in cash and equivalents against 3.59B in total debt, resulting in a net debt position of 2.92B. Total book value stands at -911.11M, with working capital of -571.54M providing operational flexibility.
| Cash & Cash Equivalents | 670.72M |
| Total Debt | 3.59B |
| Net Debt | 2.92B |
| Equity (Book Value) | -911.11M |
| Book Value Per Share | -2.83 |
| Working Capital | -571.54M |
Core Scientific Inc produced 374.86M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -1.48B in capital expenditures, free cash flow totaled -1.10B - equivalent to -3.40 per share.
| Operating Cash Flow | 374.86M |
| Capital Expenditures | -1.48B |
| Free Cash Flow | -1.10B |
| FCF Per Share | -3.40 |
Over the twelve months ended September 30, 2026, Core Scientific Inc posted a gross margin of 41.24, reflecting its pricing power and cost economics. The operating margin of -12.19 and net profit margin of -18.62 provide insight into operational efficiency.
| Gross Margin | 41.24 |
| Operating Margin | -12.19 |
| Pretax Margin | -36.16 |
| Profit Margin | -18.62 |
| EBITDA Margin | -62.53 |